Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb age and immunization-schedule bridging study of a quadrivalent recombinant HPV vaccine in girls and women
CTR20243996Phase 3Active
- Sponsor
- Chengdu Institute of Biological Products
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle in human papillomavirus infection, anogenital warts, cervical intraepithelial neoplasia (CIN), cervical carcinoma in situ, Cervical Cancer (CC), sponsored by Chengdu Institute of Biological Products. Started Nov 2025; status: active.
02
Drugs
quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle
03
Conditions
human papillomavirus infectionanogenital wartscervical intraepithelial neoplasia (CIN)cervical carcinoma in situCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20243996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243996.